Sugi Predict

Sugi Predict / Compounds / SCHEMBL3333808

SCHEMBL3333808

SCHEMBL3333808

O=C(NC1(CO)CCNCC1)OCc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TLR2 O60603 2/20 0.47
▸ CTSS P25774 3/20 0.46
▸ CTSL P07711 2/20 0.46
▸ CTSB P07858 2/20 0.46
▸ LMNA P02545 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CA12 O43570 2/20 0.43
▸ CA1 P00915 2/20 0.43
▸ CA2 P00918 2/20 0.43
▸ CA9 Q16790 2/20 0.43
▸ ALDH1A1 P00352 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ TACR1 P25103 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ CTSK P43235 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339610 1.00 TLR2 (0.47) TLR2CTSSCTSLCTSBLMNA
Hydrochloric Acid SCHEMBL19641048 1.00 TLR2 (0.47) TLR2CTSSCTSLCTSBLMNA
SCHEMBL23387355 0.92 CTSB (0.44) TLR2CTSSCTSLCTSBLMNA
SCHEMBL381668 0.90 CTSL (0.50) CTSSCTSLCTSBLMNASMN1; SMN2
Hydrochloric Acid SCHEMBL19641072 0.90 TLR2 (0.46) TLR2CTSSCTSLCTSBLMNA
SCHEMBL605067 0.88 TLR2 (0.45) TLR2CTSSCTSLCTSBLMNA
SCHEMBL24187757 0.87 CTSL (0.51) CTSSCTSLCTSBLMNASMN1; SMN2
SCHEMBL648487 0.87 CTSS (0.54) CTSSCTSLCTSBLMNASMN1; SMN2
SCHEMBL31708737 0.87 TLR2 (0.44) TLR2CTSSCTSLCTSBLMNA
SCHEMBL7121567 0.86 CTSS (0.56) CTSSCTSLCTSBLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840536-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-12-12 — — US disclosed
US-11840536-B2 Heterocyclic inhibitors of PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-12-12 — — US disclosed
US-20230109858-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-13 — — US disclosed
EP-3463343-B1 HETEROCYCLIC INHIBITORS OF PTPN11 UNIV TEXAS (US) 2022-03-23 — — EP disclosed
EP-3463343-B1 HETEROCYCLIC INHIBITORS OF PTPN11 UNIV TEXAS (US) 2022-03-23 — — EP disclosed
US-20210317122-A1 SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 Cantero Therapeutics, Inc. 2021-10-14 — — US disclosed
CN-109475531-B Heterocyclic inhibitors of PTPN11 得克萨斯州立大学董事会 2021-08-17 — — CN disclosed
US-10954243-B2 Substituted heterocyclic inhibitors of PTPN11 NAVIRE PHARMA, INC. (US) 2021-03-23 — — US disclosed
US-20210017182-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-01-21 — — US disclosed
US-20210017182-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2021-01-21 — — US disclosed
CN-109475531-A The heterocycle inhibitor of PTPN11 得克萨斯州立大学董事会 2019-03-15 — — CN disclosed
WO-2017210134-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2017-12-07 — — WO disclosed
WO-2017210134-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2017-12-07 — — WO disclosed
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-11-30 — — US disclosed
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-11-30 — — US disclosed
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-11-30 — — US disclosed
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-06-10 — — US disclosed
CN-101679422-A Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC 2010-03-24 — — CN disclosed
EP-2139888-A2 IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-01-06 — — EP disclosed
WO-2008121687-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342078-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP TLR2 3341/4885CTSS 4079/4885CTSL 4699/4885
US-20100144751-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS PIM1, PIM3, PIM2 TLR2 1457/4885CTSS 4604/4885CTSL 4311/4885
US-20210017182-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP TLR2 3341/4885CTSS 4079/4885CTSL 4699/4885
US-20230109858-A1 HETEROCYCLIC INHIBITORS OF PTPN11 PTPRJ, PTPN11, PTPRCAP TLR2 3341/4885CTSS 4079/4885CTSL 4699/4885
US-10954243-B2 Substituted heterocyclic inhibitors of PTPN11 PTPN11, PTPRJ, PTPRCAP TLR2 2926/4885CTSS 3996/4885CTSL 4659/4885
US-20210317122-A1 SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11 PTPN11, PTPRJ, PTPRCAP TLR2 2926/4885CTSS 3996/4885CTSL 4659/4885
US-11840536-B2 Heterocyclic inhibitors of PTPN11 PTPRJ, PTPN11, PTPRCAP TLR2 3341/4885CTSS 4079/4885CTSL 4699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.